208 related articles for article (PubMed ID: 36713391)
1. Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of
Zhu L; Guo Z; Zhao D; Sa R; Zhao G; Guo H; Chen G
Front Immunol; 2022; 13():1087597. PubMed ID: 36713391
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Splenic Irradiation for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Allograft Recipients With
Zhu L; Guo Z; Sa R; Guo H; Li J; Chen G
Front Immunol; 2021; 12():661614. PubMed ID: 33936098
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
4. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
5. Upfront use of eculizumab to treat early acute antibody-mediated rejection after kidney allotransplantation and relevance for xenotransplantation.
Schwotzer N; Paganetti G; Barchi M; Perrottet N; Aubert V; Sadallah S; Rotman S; Venetz JP; Matter M; Golshayan D; Pascual M
Xenotransplantation; 2020 Jul; 27(4):e12630. PubMed ID: 32698246
[TBL] [Abstract][Full Text] [Related]
6. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
Ding Y; Francis J; Gautam A; Pelletier L; Sanchorawala V; Quillen K
Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
[TBL] [Abstract][Full Text] [Related]
7. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
[TBL] [Abstract][Full Text] [Related]
8. CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection.
Doberer K; Kläger J; Gualdoni GA; Mayer KA; Eskandary F; Farkash EA; Agis H; Reiter T; Reindl-Schwaighofer R; Wahrmann M; Cohen G; Haslacher H; Bond G; Simonitsch-Klupp I; Halloran PF; Böhmig GA
Transplantation; 2021 Feb; 105(2):451-457. PubMed ID: 32235256
[TBL] [Abstract][Full Text] [Related]
9. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
[TBL] [Abstract][Full Text] [Related]
10. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury.
Yamamoto T; Watarai Y; Takeda A; Tsujita M; Hiramitsu T; Goto N; Narumi S; Katayama A; Morozumi K; Uchida K; Kobayashi T
Transplantation; 2016 Oct; 100(10):2194-202. PubMed ID: 26636737
[TBL] [Abstract][Full Text] [Related]
11. Antibody-mediated rejection with detection of de novo donor-specific anti-human leukocyte antigen Class II antibodies after lung transplantation: Problems in diagnosis, treatment and monitoring on a case report basis.
Dukat-Mazurek A; Stachowicz-Chojnacka K; Karolak W; Zielińska H; Moszkowska G; Kałęka P; Wojarski J; Żegleń S
Transpl Immunol; 2023 Dec; 81():101918. PubMed ID: 37598914
[TBL] [Abstract][Full Text] [Related]
12. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
[TBL] [Abstract][Full Text] [Related]
13. Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation.
Yerly P; Rotman S; Regamey J; Aubert V; Aur S; Kirsch M; Hullin R; Pascual M
Xenotransplantation; 2022 Jan; 29(1):e12726. PubMed ID: 35001433
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Antibody-Mediated Rejection After Kidney Transplantation: Immunological Effects, Clinical Response, and Histological Findings.
de Sousa MV; Gonçalez AC; de Lima Zollner R; Mazzali M
Ann Transplant; 2020 Nov; 25():e925488. PubMed ID: 33199675
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use.
Kwun J; Matignon M; Manook M; Guendouz S; Audard V; Kheav D; Poullot E; Gautreau C; Ezekian B; Bodez D; Damy T; Faivre L; Menouche D; Yoon J; Park J; Belhadj K; Chen D; Bilewski AM; Yi JS; Collins B; Stegall M; Farris AB; Knechtle S; Grimbert P
J Am Soc Nephrol; 2019 Jul; 30(7):1206-1219. PubMed ID: 31227636
[TBL] [Abstract][Full Text] [Related]
16. Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection.
Ginevri F; Nocera A; Comoli P; Innocente A; Cioni M; Parodi A; Fontana I; Magnasco A; Nocco A; Tagliamacco A; Sementa A; Ceriolo P; Ghio L; Zecca M; Cardillo M; Garibotto G; Ghiggeri GM; Poli F
Am J Transplant; 2012 Dec; 12(12):3355-62. PubMed ID: 22959074
[TBL] [Abstract][Full Text] [Related]
17. Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection.
Orandi BJ; Lonze BE; Jackson A; Terezakis S; Kraus ES; Alachkar N; Bagnasco SM; Segev DL; Orens JB; Montgomery RA
Am J Transplant; 2016 Oct; 16(10):3041-3045. PubMed ID: 27214874
[TBL] [Abstract][Full Text] [Related]
18. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
[TBL] [Abstract][Full Text] [Related]
20. Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients.
Lee H; Min JW; Kim JI; Moon IS; Park KH; Yang CW; Chung BH; Oh EJ
Medicine (Baltimore); 2016 Mar; 95(11):e3094. PubMed ID: 26986147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
